New pill aims to quiet heartburn without damaging the esophagus
NCT ID NCT07160790
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new drug called JP-1366 for people with non-erosive gastroesophageal reflux disease (NERD), a condition causing heartburn without visible damage to the esophagus. About 321 adults will take either JP-1366 or a placebo daily. The main goal is to see if the drug increases the number of days without heartburn.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- JP-1366 (a drug for acid reflux)
- What this could lead to
- If it works, this could provide a new treatment option to reduce heartburn in people with non-erosive reflux disease.
- What could go wrong
- This is a Phase 3 trial, but results may not confirm benefit. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 321 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects who have experienced both heartburn and acid regurgitation * Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification * Subjects who fully understand this clinical trial and voluntarily signed the informed consent form Exclusion Criteria: * Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum * Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI/P-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions. * Subjects who showed clinically significant abnormalities in laboratory tests * Positive result in the H. pylori test * Pregnant or breast-feeding women * Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia * Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-erosive gastroesophageal reflux disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.